Funding Decisions


Movember Discovery Grants

October 31, 2016 - Prostate Cancer Canada and Movember are proud to announce the successful recipients of the 2016 Movember Discovery Grants competition. The main goal of this program is to support researchers in that key stage of obtaining early results. The program supports both junior investigators early in their career and  more established investigators to pursue new important directions. Applications are accepted from all areas of prostate cancer research. The goal is to support researchers to generate preliminary data in prostate cancer research that would provide the basis for a more substantial research grant in the future. The applications are evaluated by a rigorous peer-review process that assesses innovation, the track record of investigator and team, the feasibility of the proposed work and the potential impact on prostate cancer.

This represents an investment of $2,270,968 over 2 years starting July 1, 2016.
 
Principal Investigator Institution Title Funded Amount
Richard Baverstock University of Calgary
Calgary, AB
Measuring the relationship between overactive bladder symptoms and prostate cancer treatment: is it bi-directional? $186,904
Vincent Fradet Université Laval
Quebec, QC
Role of gut microbiota on anti-inflammatory effect of Omega-3 in prostate cancer $197,944
Roseline Godbout University of Alberta
Edmonton, AB
Role of a novel fatty acid binding protein (FABP12) in prostate cancer lipid metabolism and progression $199,820
Housheng He University Health Network
Toronto, ON
Identifying functional long noncoding RNAs in prostate cancer $198,000
Madhuri Koti Queen's University
Kingston, ON
PTEN regulated interferon pathways as novel therapeutic targets in prostate cancer $198,000
Shawn Li Western University
London, ON
Global and quantitative kinomic and phosphoproteomic analysis of advanced prostate cancer to enable effective treatment $200,000
Hongshen Ma University of British Columbia
Vancouver, BC
Investigating castrate resistant prostate cancer through transcriptome profiling of single CTCs $200,000
Septimu Salcudean University of British Columbia
Vancouver, BC
Quantitative multimodal imaging of prostate cancer $184,108
Paul Toren Université Laval
Quebec, QC
The role of serum steroids in the development of castrate resistant prostate cancer: a secondary analysis of the PR.7 trial $115,192
Yuzhuo Wang University of British Columbia
Vancouver, BC
Identification of potential therapeutic targets for AR pathway inhibitor-resistant prostate cancer $200,000
Jian Hui Wu Lady Davis Institute for Medical Research
Montreal, QC
Development of novel GATA2 inhibitors for breaking the critical AR-GATA2 feedback loop in castration-resistant prostate cancer
$191,000
Frank Wuest University of Alberta
Edmonton, AB
Silicon-fluorine-PSMA: a winning team for early prostate cancer detection $200,000


Personnel Awards in Prostate Cancer Research


October 25, 2016 - Prostate Cancer Canada is proud to announce the recipients of the 2016 Personnel Awards in Prostate Cancer Research. These awards are available to outstanding doctoral students, post- doctoral fellows and clinical research fellows studying prostate cancer. They provide recognition and funding early in academic research careers with an opportunity to continue training in an outstanding research environment.
 
This represents an investment of $495,000 over 2 years starting July 1, 2016.

 

Award Awardee Institution Title Award Amount
Great Gulf Post-Doctoral Research Fellowship Jennifer Bossio University of British Columbia
Vancouver, BC
Advances in the treatment of sexual dysfunction for men following prostate cancer: Applications for mindfulness-based cognitive therapy (MBCT) $105,000
Ellis Don Post-Doctoral Research Fellowship Lindsay Hedden University of British Columbia
Vancouver, BC
Evidence-informed decision making in cancer survivorship: evaluating a comprehensive, multi-disciplinary prostate cancer supportive care program $105,000
Paul Flumian Post-Doctoral Research Fellowship Ravi Shashi Nayana Munuganti University of British Columbia
Vancouver, BC
Development of Neural Transcription Factor BRN2 Inhibitors as Potential Therapeutics for Neuroendocrine Prostate Cancer $105,000
Stewart McInnes Post-Doctoral Research Fellowship Guy Nir University of British Columbia
Vancouver, BC
Radiomic Profiling Based on Digital Pathology for Improving Patient Stratification in Prostate Cancer Management $105,000
Philip Feldberg Graduate Studentship Natalie Fox University of Toronto/ Ontario Institute for Cancer Research
Toronto, ON
Characterization and clinical consequences of genome-transcriptome associations in intermediate risk prostate cancer $75,000


 

Movember Translation Acceleration Grants 2016

October 25, 2016 - Prostate Cancer Canada is pleased to announce the successful candidates from the Translation Acceleration Grants 2016 competition.  Grants are meant to address a significant issue in the management of prostate cancer, with a high potential of preventing disease progression and/or improving quality of life in the short term. The grants should leverage existing knowledge and have the capability to accelerate impact. The emphasis of this funding opportunity is to develop an intervention that can be studied in a patient or population study within a 5-year timeframe.
This opportunity is proudly funded by the Movember Foundation and represents a total investment of $4,477,177 over three years commencing April 1, 2016. 

 

Principal Investigator Institution Title Funded Amount
Bernhard Eigl BC Cancer Agency
Vancouver, BC
The PRIME Study - PRevention and Intervention for MEtabolic syndrome $1,498,452
Martin Gleave University of British Columbia
Vancouver, BC
Computer-aided design of novel inhibitors of Hsp27 $1,480,000
Laurence Klotz Canadian Urology Research Consortium
Toronto, ON
A randomised controlled trial of magnetic resonance imaging-targeted biopsy compared to standard trans-rectal ultrasound guided biopsy for the diagnosis of prostate cancer in men without prior biopsy $1,498,725


Special Project in Non-Metastatic Castrate Resistant Prostate Cancer

April 5, 2016 – Prostate Cancer Canada is pleased to announce the successful candidate from the Special Project in Non-Metastatic Castrate Resistant Prostate Cancer (NM-CRPC) competition. This award solicits proposals from groups interested in combining various real world data sources (i.e. detailed chart review at prostate cancer centres with health administrative databases) to obtain high quality epidemiological data, outcomes and costs among the population of prostate cancer patients in at least two provinces in Canada that together represent greater than 50% of the population.
 
The key objectives of this program are:

  • to obtain prevalence, incidence and survival probability estimates of prostate cancer, stratified by age and year of diagnosis from provincial cancer registries;
  • to identify pathways leading to and factors associated with the target condition (NM-CRPC);
  • to estimate annual incidence and prevalence of NM-CRPC, stratified probability of developing NM-CRPC and transition probabilities that characterize the prognosis from NM-CRPC to metastasis and end-of-life;
  • to estimate health care resource use and costs for health states in the recurrent disease model.
This opportunity represents a total investment of $425,437 over two years.  
 
Principal
Investigator
Institution Title Funded Amount
Murray Krahn University Health Network
Toronto, ON
Non-metastatic castrate resistant prostate cancer: epidemiology, clinical pathways, and health care costs $425,437


Movember Rising Stars in Prostate Cancer Research

December 16, 2015 – Prostate Cancer Canada is pleased to announce the successful candidates from the Rising Stars in Prostate Cancer Research competition. These awards provide salary and research support for outstanding researchers within the first 5 years of their first academic or research appointment to develop and demonstrate independence in a career in prostate cancer research.

This opportunity, proudly funded by the Movember Foundation, represents a total investment of $1,345,199. Each award is for three years to a maximum of $450,000.

Principal
Investigator
Institution Title Funded Amount
Housheng He University Health Network
Toronto, ON
Epigenetic mechanisms underlying prostate cancer development and progression $445,200
Hon Leong Lawson Health Research Institute
London, ON
Antagonizing molecular mechanisms responsible for cancer cell extravasation to combat prostate cancer metastasis $450,000
Alexander Wyatt University of British Columbia
Vancouver, BC
Detecting druggable DNA repair defects in advanced prostate cancer $449,999

Movember Team Grant

June 10, 2015 - Prostate Cancer Canada and Movember are proud to announce the recipient of the 2015 Movember Team Grant. Team grant funding supports integrated, multi-disciplinary research programs involving high-quality independent investigators who share knowledge and resources while working towards a unifying overall scientific goal. The successful team must propose a well-defined program of research that encompasses several aspects of prostate cancer research that are clearly interrelated and synergistic so that efforts and outcomes have more impact than if funded as separate grants. The program must have participating principal investigators from a minimum of three institutions and provide a formal training program.  

An international panel of reviewers was assembled to adjudicate the team grants competition. The applications were submitted to a multi-stage and layered review process; narrowing the field to a short list of applicant teams invited to a reverse site visit in Toronto.

This represents a total investment of $4,995,400 over five years starting July 1, 2015.

 
Program Director and Principal Investigator Institution Title Funded Amount
John Bell Ottawa Hospital Research Institute
Ottawa, ON
Development of a targeted oncolytic virus vaccine for the treatment of metastatic prostate cancer $4,990,498
Team Members: Institutions:
Jean-Simon Diallo
Co-Principal Investigator
Ottawa Hospital Research Institute
Ottawa, ON
Sébastien Hotte
Co-Principal Investigator
McMaster University
Hamilton, ON
Brian Lichty
Co-Principal Investigator
McMaster University
Hamilton, ON
Fred Saad
Co-Principal Investigator
Centre Hospitalier de l'Université de Montréal
Montreal, QC
Eric Belanger
Co-Investigator
Ottawa Hospital
Ottawa, ON
Jonathan Bramson
Co-Investigator
McMaster University
Hamilton, ON
Rodney Breau
Co-Investigator
Ottawa Hospital Research Institute
Ottawa, ON
Dean Fergusson
Co-Investigator
Ottawa Hospital Research Institute
Ottawa, ON
Derek Jonker
Co-Investigator
University of Ottawa
Ottawa, ON
Andrea McCart
Co-Investigator
University of Toronto
Toronto, ON
David Stojdl
Co-Investigator
Children's Hospital of Eastern Ontario
Ottawa, ON
Yonghong Wan
Co-Investigator
McMaster University
Hamilton, ON

 

Movember True NTH Survivorship Research Grants

March 27, 2015 - Prostate Cancer Canada (PCC) and Movember are proud to announce the results of the Movember Targeted RFA in Survivorship Research competition. Projects aim to inform the development and delivery of interventions and best practices in follow-up care for cancer patients, survivors and their families and caregivers.

Three grants have been funded starting April 1, 2015, representing a total investment of $2,065,895 over the next three to five years.
 
Principal Investigator Institution Title Funded Amount
Shabbir Alibhai University Health Network
Toronto, ON
Toward personalizing care for older men with mCRPC - Princess Margaret Cancer Centre, University Health Network and predicting treatment toxicities
(the TOPCOP study)
$413,830
Jennifer Jones University Health Network
Toronto, ON
Prostate Cancer Survivorship 360° $1,281,025
Sylvie Lambert McGill University
Montreal, QC
Reducing anxiety and enhancing quality of life among caregivers of prostate cancer survivors: Development and evaluation of a dyadic, tailored, web-based, psychosocial and physical activity self-management programme $434,040

 

Movember Clinical Trial in Prostate Cancer

March 20, 2015 - Prostate Cancer Canada (PCC) and Movember are proud to announce the results of the Movember Clinical Trials in Prostate Cancer competition. Applications were accepted for investigator-initiated clinical trials studying the iatrogenic effects of prostate cancer treatment with an overall aim of mitigating effects that are unintended and unwanted.

One grant has been funded starting April 1, 2015, representing a total investment of $3,449,136 over a five-year term.

 
Principal Investigator Institution Title Funded Amount
Jehonathan Pinthus McMaster University
Hamilton, ON
Role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC) $3,449,136
 
 




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Thank You to our Canadian Mo Bros and Sistas!

TORONTO, December 1, 2016 - Prostate Cancer Canada congratulates the more than 500,000 Mo Bros and Mo Sistas worldwide who participated in this year's Movember campaign.
More

The Parking Lot Prostate Exam Project #TalkProstate

To stimulate public discussion about prostate cancer and the importance of early detection, Prostate Cancer Canada teamed up with FCB Canada and CFL legend Damon Allen during Prostate Cancer Awareness Month to help get a serious message across through a fun campaign.
More

The future of prostate cancer research looks bright

Toronto, ON – September 19, 2016:  Continuing with its ongoing commitment to ensure the future of prostate cancer research in Canada is left in the best possible hands, Prostate Cancer Canada (PCC) has chosen four postdoctoral fellows and one PhD candidate as the recipients for this year’s prestigious personnel awards.
More


Click here for news archive